

UCLA

UCLA Previously Published Works

Title

Neurotoxicity of the Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos

Permalink

<https://escholarship.org/uc/item/3rt4r391>

Journal

Environmental Health Perspectives, 124(11)

ISSN

1542-4359

Authors

Lulla, Aaron

Barnhill, Lisa

Bitan, Gal

et al.

Publication Date

2016-11-01

DOI

10.1289/ehp141

Peer reviewed

Neurotoxicity of the Parkinson's Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos

Aaron Lulla, Lisa Barnhill, Gal Bitan, Magdalena I. Ivanova, Binh Nguyen, Kelley O'Donnell, Mark C. Stahl, Chase Yamashiro, Frank-Gerrit Klärner, Thomas Schrader, Alvaro Sagasti, and Jeff M. Bronstein

<http://dx.doi.org/10.1289/EHP141>

Received: 24 October 2015

Revised: 21 February 2016

Accepted: 12 May 2016

Published: 15 June 2016

Note to readers with disabilities: *EHP* will provide a [508-conformant](#) version of this article upon final publication. If you require a 508-conformant version before then, please contact ehp508@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

Neurotoxicity of the Parkinson's Disease-Associated Pesticide Ziram Is Synuclein-Dependent in Zebrafish Embryos

Aaron Lulla¹, Lisa Barnhill¹, Gal Bitan^{1,5,6}, Magdalena I. Ivanova^{2,7}, Binh Nguyen¹, Kelley O'Donnell³, Mark C. Stahl¹, Chase Yamashiro¹, Frank-Gerrit Klärner⁸, Thomas Schrader⁸, Alvaro Sagasti³, and Jeff M. Bronstein^{1,4,5}

¹Departments of Neurology, ²Chemistry and Biochemistry, ³Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, California, USA; ⁴Parkinson's Disease Research, Education, and Clinical Center, Greater Los Angeles Veterans Affairs Medical Center, Los Angeles, California, USA; ⁵Brain Research Institute, ⁶Molecular Biology Institute, and ⁷UCLA-DOE Institute, UCLA, Los Angeles, California; ⁸Institute of Organic Chemistry, University of Duisburg-Essen, Essen 45117, Germany.

Address correspondence to Jeff M. Bronstein, David Geffen School of Medicine at UCLA, Department of Neurology, 710 Westwood Plaza, Los Angeles, CA 90095-1769 USA.

Telephone: 310 206-9799. E-mail: jbronste@mednet.ucla.edu.

Magdalena I. Ivanova's present address: Department of Neurology and Program of Biophysics, University of Michigan, Ann Arbor, MI 48109. Mark C Stahl's present address: Department of Neurology, Pennsylvania State University Milton S. Hershey Medical Center, Hershey, PA 17033.

Running title: Neurotoxicity of Ziram is Synuclein Dependent

Acknowledgments: These studies were supported by grants from NIEHS (JMB: P01ES016732 and 5R21ES16446-2, AL and LB: T32ES01545), the Veterans Administration Healthcare

System (SW PADRECC, JMB), The Levine Foundation, and the Parkinson Alliance (JMB and GB). We acknowledge the generous support by the UCLA Jim Easton Consortium for Alzheimer's Disease Drug Discovery and Biomarker Development (G.B.), and the Judith & Jean Pape Adams Charitable Foundation (GB). University of Michigan Protein Folding Diseases Initiative (MII)

Conflict of Interests: GB, F-GK, and TS are co-inventors of US patent No. 8,791,092 and European Patent Application 10 708 075.6, Molecular Tweezers for the Treatment of Amyloid-Related Diseases. The other authors declare they have no actual or potential competing financial interests.

Abstract

Exposure to the commonly used dithiocarbamate (DTC) pesticide ziram is associated with an increased risk of developing Parkinson's disease (PD), although the mechanisms of toxicity are not completely understood. In this study, we utilized zebrafish (ZF) embryos to study the mechanisms of ziram's neurotoxicity *in vivo*. Nanomolar concentrations of ziram caused selective loss of dopaminergic (DA) neurons and impaired swimming behavior. Since ziram increases α -synuclein (α -syn) concentrations in rat primary neuronal cultures, we investigated the effect of ziram on ZF γ -synuclein 1 (γ 1). ZF express 3 synuclein isoforms and ZF γ 1 appears to be a functional homologue of α -syn. We found that recombinant ZF γ 1 formed fibrils *in vitro* and overexpression of ZF γ 1 in ZF embryos led to the formation of neuronal aggregates and neurotoxicity similarly to α -syn. Importantly, knockdown of ZF γ 1 with morpholinos or disruption of oligomers with the molecular tweezer CLR01 prevented ziram's DA toxicity. These data demonstrate that ziram is selectively toxic to DA neurons *in vivo* and this toxicity is synuclein-dependent. These findings have important implications for understanding the mechanisms by which pesticides may cause PD.

Introduction

Parkinson's disease (PD) is a neurodegenerative disease that affects millions of individuals worldwide (Dorsey et al. 2007). Although significant progress has been made in understanding the pathophysiology of PD, the etiology is still not well understood. There does not appear to be one simple cause of PD but it likely develops from complex genetic and environmental interactions.

Several lines of evidence have implicated the involvement of α -synuclein (α -syn) in the pathogenesis of PD. The identification of mutations in the α -syn- (SNCA) gene led to the finding that α -syn is the major component of Lewy Bodies the pathological hallmark of PD, not only in these patients, but also in sporadic PD (Baba et al. 1998; Chartier-Harlin et al. 2004; Farrer et al. 2004; Ibanez et al. 2004; Kruger et al. 1998; Nishioka et al. 2006; Polymeropoulos et al. 1997; Singleton et al. 2003; Spillantini et al. 1997). Additionally, overexpression of wild-type (WT) α -syn by gene multiplication causes fairly typical PD (Hope et al. 2004). Furthermore, people who carry an allele in the α -syn promoter (REP1 263) that confers a higher level of expression are at higher risk of developing PD (Maraganore et al. 2006). Thus, increased expression of α -syn increases the risk of developing PD and if expression is doubled or more, one will get the disease. REP1 263 is also associated with faster progression of PD adding further support for the concept that increased levels of α -syn is central to the pathogenesis of PD (Ritz et al. 2012). More recently, evidence is building that α -syn expression may also interact with environmental factors to increase the risk of developing the disease. For example, the REP1 263 allele, influences susceptibility to damage from paraquat exposure and head trauma (Gatto et al. 2010; Goldman et al. 2012).

The genetics of PD have been extensively studied but only account for a small percentage of patients with PD, suggesting that environmental factors play an important role (International Parkinson Disease Genomics et al. 2011; Trinh and Farrer 2013). Epidemiological studies have demonstrated that pesticide exposure is associated with an increased risk of developing PD (Brown et al. 2006; Goldman 2014) and a causal role for this association is supported by cell-based and animal studies (Betarbet et al. 2000; Chou et al. 2008; Fitzmaurice et al. 2013; McCormack et al. 2002; Ryan et al. 2013; Thiruchelvam et al. 2000; Wang et al. 2006). Interestingly, the mechanisms by which pesticides increase disease risk appear to be diverse. Proposed mechanisms include mitochondrial inhibition, oxidative stress, impaired protein degradation, and aldehyde dehydrogenase (ALDH) inhibition (Barnhill and Bronstein 2014; Goldman 2014).

One pesticide of particular interest is the dithiocarbamate (DTC) fungicide ziram. Residential and workplace exposure to ziram is associated with a three fold increased risk for developing PD and as high as six fold for early onset cases (Wang et al. 2011). Additionally *in vitro* and *in vivo* exposure studies have shown that ziram is toxic to dopaminergic (DA) neurons in rat primary neuronal cultures (Chou et al. 2008). The mechanism of ziram's DA toxicity appears to be, at least in part, related to its ability to impair protein degradation by inhibiting E1 ligase of the ubiquitin proteasome system (UPS) and causing accumulation of α -syn (Chou et al. 2008).

Despite the progress that has been made in understanding the mechanisms of ziram's toxicity, *in vivo* studies are lacking. One reason for this is that testing in rodent models is very expensive and time consuming. Zebrafish (*Danio rerio*, ZF) are a powerful model organism to study the effects of environmental toxins and neurodegenerative diseases since they are rapidly

developing vertebrates with a well- formed DA neuronal network similar to that of mammals (Bretau et al. 2007; Milanese et al. 2012; Schweitzer et al. 2012; Sheng et al. 2010; Wen et al. 2008; Xi et al. 2011), have many orthologues to human drug targets (Gunnarsson et al. 2008), and alterations in homeostasis of proteins associated with PD have been found to cause similar effects in ZF and other model organisms (Betarbet et al. 2000; Feany and Bender 2000; Prabhudesai et al. 2012). Here, we utilized ZF to further study the neurotoxicity of ziram *in vivo* and found that exposure to low concentrations led to damaged DA neurons and abnormal motor behavior. ZF do not have an orthologue to human α -syn but ZF γ -synuclein 1 (γ 1) appears to be functionally similar to α -syn (Milanese et al. 2012). ZF γ 1 was found to form fibrils when overexpressed like human α -syn. Importantly, ziram's toxicity was found to be ZF γ 1-dependent.

Materials and Methods

Zebrafish

ZF lines (AB unless otherwise stated) were bred and maintained at 28 °C in recirculating water tanks on a regulated 14h light/10h dark cycle and fed twice a day with brine shrimp. All experiments were carried out in accordance with UCLA Animal Research Committee protocols. ZF expressing GFP driven by the vesicular monoamine transporter promoter (VMAT2:GFP) were purchased from the UCLA core facility and used in this study to identify VMAT2 (dopaminergic, (nor)adrenergic, serotonergic) neurons in whole embryos (Wen et al. 2008). Peripheral sensory neurons (trigeminal and Rohon-Beard) were visualized using the $Tg(isl1[ss]:Gal4-VP16,UAS:EGFP)^{zf154}$ transgenic line, which has been referred to as $Tg(sensory:GFP)$, and were obtained from Dr. Sagasti (Sagasti et al. 2005).

A ZF γ 1-synuclein expression construct (γ 1-DsRed) composed of a T2A bicistronic configuration, driven by the *HuC* neuronal promoter and expressing monomeric DsRed, was used as previously described (Prabhudesai et al. 2012). The T2A sequence is cleaved after translation generating two proteins from a single open reading frame and resulting in stoichiometric expression of the gene of interest and the fluorescent reporter (Tang et al. 2009). ZF embryos were injected with *HuC*-ZF γ 1-T2A-DsRed or *HuC*-DsRed (control) cDNA (50ng/ μ L) at the single cell stage.

Morpholinos (Gene Tools LLC, Philomath OR) were injected (0.1mM) at the single-cell stage for ZF γ 1 (CATTAGAACATCCATCCTGGACGCT, translational blocking) or non-targeting/scrambled (CCTCTTACCTCAGTTACAATTTATA), as previously described (see Fig. S1) (Milanese et al. 2012). The molecular tweezers CLR01 and CLR03 were prepared and purified as sodium salts, as described previously (Fokkens et al. 2005; Talbiersky et al. 2008). Specificity of the ZF γ 1 morpholino (MO) was validated by SDS PAGE (see Fig. S1d).

Zebrafish Treatments

ZF embryos, 25-35 per treatment in 10 mL of E3 media (15mM NaCl, 0.5mM KCl, 1.0mM MgSO₄, 0.15mM KH₂PO₄, 0.05mM Na₂HPO₄, 1.0mM CaCl₂, 0.7mM NaHCO₃), were reared at 32 °C and exposed to varying concentrations of ziram (98.5% purity, Chem Service, West Chester PA). Embryos were exposed to 1 nM-1 μ M (0.01%DMSO) ziram in E3 media at 5 hours post-fertilization (hpf) or 24 hpf in a 6-well plate for 5 days for confocal microscopy and 7 days post fertilization (dpf) for behavior. The concentrations of ziram used for the study were well below those used for spraying (approximately 8 mM) (Agency 2015) and necessary for fungicidal activity (30 μ M) (Briquet et al. 1976). VMAT2:GFP embryos were co-treated with

10 μ M CLR01 (Fokkens et al. 2005; Prabhudesai et al. 2012; Sinha et al. 2011) and 50nM ziram.

Log-Rank test was used for statistical analysis.

Confocal Microscopy

VMAT2:GFP embryos (3 dpf and 5 dpf) were anesthetized using Tricane-S (Western Chemicals Inc., Ferndale WA) at a final concentration 50 μ g/mL, fixed in 4% paraformaldehyde (PFA) overnight and mounted in 2% low-melting agarose. Embryos were imaged at 20X using a Zeiss LSM 510 microscope. Approximately 100 1.1 μ m optical sections were obtained for each embryo. Section images were stacked and reconstituted into 2D and 3D images using ImageJ (National Institutes of Health). Neuron count analyses were conducted in a blinded manner as previously described (Fitzmaurice et al. 2013). For MO and CLR01 studies, neuron counts for treatment groups were normalized to injection and treatment controls to account for variances in fish clutches between days and for treatment and injection survival. Student's t-test was used for statistical analysis

Histology

ZF embryos were dechorinated at 2 dpf, fixed in 4% PFA for 24 hours, immersed in 30% sucrose overnight and cryosectioned (10- μ m). For thioflavin S (ThS) staining, sections were immersed in 0.5% ThS dissolved in PBS (Sigma-Aldrich, St. Louis MO), washed with ethanol (80%), and then mounted with Vectashield+Dapi (Vector Laboratories, Burlingame CA).

Polyclonal antibodies specific for ZF γ 1 were raised using a C-terminal peptide CDFSHGGMEGGEGGE (Genscript, Piscataway NJ). These antibodies bound specifically to ZF γ 1 at the predicted mass (17 kDa) in ZF embryos and to recombinant γ 1 (see Fig. S1a).

Furthermore, the ZF γ 1 band in Western blots was markedly reduced in ZF after pre-absorption

with the ZF $\gamma 1$ peptide used to raise the antibody (see Fig. S1c). Anti-ZF $\gamma 1$ antibodies did not recognize any rodent brain proteins (see Fig. S1a).

For immunohistochemistry, sections were blocked in 10% normal goat serum (Jackson Labs, Bar Harbor ME), incubated with anti-ZF $\gamma 1$ antibody (1:1000) followed by incubation with an anti-rabbit-Alexa-Fluor 568 antibody (1:500, Life Technologies, Grand Island NY). The sections were then mounted with Vectashield+Dapi.

Behavioral Analysis

ZF embryos (7 dpf) were placed in 10mL of E3 media and kept in the dark to avoid degradation of added chemicals. Drug or vehicle (5 μ M apomorphine, 25 μ M haloperidol or 0.1% DMSO) were added and incubated for 30-minutes at 28°C prior to behavioral analysis. Twelve fish from each treatment group were transferred to a square 96-well plate and maintained in the dark for 10 minutes prior to behavioral analysis, which consisted of 10-minute alternating cycles of light (100% light as specified by Zebralab, View Point, France) and dark (total 30 minutes in light and 30 minutes in dark). Movements greater than 2 millimeters were collected every two minutes using the Zebralab system and analyzed for distance traveled. Embryos with notochord malformations were excluded for behavioral analysis. Data were normalized to vehicle controls to account for variances between fish clutches from different days. One-way ANOVA was used for statistical analysis.

Western and Native Blots

ZF embryos (5 dpf) were anesthetized as described above, pooled (35 embryos per treatment), de-yolked, lysed, and sonicated in either 1X-SDS buffer or 1X-Native PAGE sample buffer (Life Technologies). Protein concentrations were determined using the BCA protein assay

(Thermo-Fisher, Rockford IL). Protein (75 μ g/lane) was loaded onto SDS-PAGE or Native-PAGE gels and transferred using the XCell-II blotting system (Life Technologies). Membranes were probed with ZF γ 1 1 $^{\circ}$ antibody (1:2500 dilution), or TH 1 $^{\circ}$ antibody (1:2500, MAB 318: Millipore) followed by donkey anti-rabbit HRP 2 $^{\circ}$ antibody (1:2500 dilution, Santa Cruz Biotechnology, Dallas TX). Chemiluminescent substrate (Super Signal West Dura, Thermo Scientific) was used for band visualization. α -Tubulin (1:500, Sigma-Aldrich) was used as a loading control. Student's t-test was used for statistical analysis.

Expression and purification of zebrafish synuclein

Competent BL21 (DE3) E. Coli bacteria were transformed with a plasmid containing the ZF synuclein gene, allowed to grow in 3 L Luria broth to $OD_{600} \approx 0.8$, induced with 0.5 mM isopropyl β -D-1-thiogalactopyranoside and incubated for 3 additional hours. The bacteria were collected by centrifugation for 15 min at $4,690 \times g$ and resuspended in 60 mL of lysis buffer containing 0.2 M Tris, 1 mM EDTA, pH 8.0, supplemented with Halt EDTA-free protease inhibitor cocktail (Thermo Scientific). The bacteria then were lysed on ice using a tip sonicator set to 3 KJoule for 3×2 min cycles of 3 sec power on and 3 sec power off. The lysate was centrifuged at $31,920 \times g$ for 20 min and the supernate was collected. The proteins were precipitated from the supernatant by addition of 0.23g/ml ammonium sulfate. The solution with the ammonium sulfate was stirred on ice for 20 min and centrifuged at $31,920 \times g$ for 20 min. The supernatant was discarded and the protein pellets were dried. The pellets were resuspended in 40 mL of 20 mM Tris, pH 8.0, and the resulting solution dialyzed overnight against 4 L of the same buffer. The crude protein mixture was fractionated using ion-exchange Q columns (GE Healthcare, Piscataway, NJ) and a 100 mL gradient ranging from 0 to 1.0 M NaCl in 20 mM Tris, pH 8.0. The protein was purified further by size exclusion chromatography using a $2.15 \times$

600 mm TSK-gel G3000SW column (Tosoh Biosciences, San Francisco, CA) with elution buffer comprising 100 mM sodium sulfate, 25 mM sodium phosphate, and 1 mM sodium azide, pH 6.5. Finally, the fractions containing purified ZF synuclein were dialyzed against 10 mM sodium phosphate, pH 7.4. The purity of the protein was assessed by SDS-PAGE and Coomassie blue staining.

Thioflavin T fluorescence assays

A concentrated protein solution was thawed on ice and filtered through a 0.2 μm filter prior to the fibril formation assay. Fibril formation assays were performed with 150- μM ZF γ1 or human $\alpha\text{-syn}$ as a positive control in 10 mM sodium phosphate, pH 7.4, and 10 μM thioflavin T (ThT). ThT is used for identification and staining of amyloid fibrils (Biancalana and Koide 2010). For inhibition assays with molecular tweezers, ZF γ1 was used at 100 μM . Stock solutions were made by dissolving CLR01 or CLR03 at 10 mM in 10 mM sodium phosphate, pH 7.4. CLR01 and CLR03 were added at the molar ratios indicated.

All assays were performed in black, Nunc 96-well optical bottom plates (Thermo Scientific). Teflon balls (1/8 inch in diameter) were distributed into each well of the 96-well plate. Then, 200 μL of solution (four replicates per sample) were pipetted into each well. The plate was agitated at 300 rpm with a 3-mm rotation diameter in a Varioskan microplate reader (Thermo Scientific) at 37 $^{\circ}\text{C}$. Fluorescence measurements were recorded every 10-15 min by using $\lambda_{\text{ex}} = 444 \text{ nm}$, $\lambda_{\text{em}} = 482 \text{ nm}$, with an integration time of 200 μs .

The ThT fluorescence signal was corrected for the background by subtracting the mean fluorescence signal acquired during the first couple of hours since the start of the assay. The fluorescence signal was normalized by dividing each measurement by the mean signal collected

for 2–4 h during which the fluorescent reading had the largest value. If one of the sample replicates had fluorescence reading close to the background, its fluorescence was normalized by dividing it by the mean fluorescence reading of the remaining replicates. The data were smoothed by substituting each data point with the average value calculated using six data points collected before and after the point and the point itself. This is equivalent to central moving average with a sliding thirteen-data-point-wide window. The normalized fluorescence signal of ZF γ 1 and CLR01 (ratio 1:1) and ZF γ 1 and CLR01 (1:10), and ZF γ 1 and CLR03 (1:10) were calculated using the averaged fluorescence signal of maximum fluorescence acquired from the assays of ZF γ 1 alone.

Transmission Electron Microscopy (TEM)

Negatively stained specimens for TEM were prepared by applying 5 μ L of sample onto hydrophilic, 400-mesh, carbon-coated formvar support films mounted on copper grids (Ted Pella, Inc.). The samples were allowed to adhere for 3 min, rinsed twice with distilled water and stained for 1 min with 1% uranyl acetate. Grids were examined on JEM1200-EX (JEOL) or T12 (FEI) microscopes.

Statistical Analysis

Statistical analyses were performed using Student's t-test, log-rank, and one-way ANOVA where appropriate. A minimum significance level was set at $p < 0.05$ for all studies.

Results

Ziram is toxic at low concentrations: ZF embryos exposed to ziram early in development resulted in marked notochord malformations (see Fig. S2 b,c) similarly to other dithiocarbamates

(Haendel et al. 2004; Teraoka et al. 2006). In order to determine the toxicity of ziram without this confound, embryos were exposed at 24 hpf, a developmental point at which the notochord is sufficiently developed. When added at 24 hpf, ziram reduced survival in a concentration-dependent manner. At 7 dpf, embryos appeared grossly normal but survival was reduced by 80% at a concentration of 100 nM or above (see Fig. S2a).

Ziram is selectively toxic to DA neurons: We previously reported that ziram was selectively toxic to DA neurons in rat primary mesencephalic cultures (Chou et al. 2008). In order to determine if ziram is also toxic to DA neurons *in vivo*, we utilized a VMAT2:GFP ZF line that expresses GFP driven by the VMAT2 promoter to monitor aminergic neuronal integrity as previously described (Fitzmaurice et al. 2013; Wen et al. 2008). We tested ziram exposure at a concentration of 50 nM since this was the highest concentration in which there was no significant degree of lethality. A decrease in the number of GFP-labeled neurons was observed in the telencephalic (TC) and diencephalic clusters (DC) (Figure 1a,b,c,d) in embryos treated with ziram. These clusters are predominantly DA although they also include some noradrenergic neurons (R. Jeroen Pasterkamp 2009; Rink and Wullimann 2002). The toxicity of ziram to DA neurons was further supported by the measured 63% decrease in tyrosine hydroxylase-1 (TH-1) protein levels (see Fig. S3). In order to determine if this toxicity was selective to aminergic neurons, we measured the integrity of Rohon-Beard neurons after exposure to 50 nM ziram using Tg(sensory:GFP) embryos as previously described (Fitzmaurice et al. 2013; Sagasti et al. 2005). No significant change in the number of labeled sensory neurons was observed compared to vehicle controls (Figure 1 e, f, and g). Furthermore, ziram appeared selectively toxic to DA neurons since serotonergic neurons in the Raphe Nuclei of the VMAT2 transgenic line were unaffected by ziram exposure (Figure 1 h,i,j).

Ziram alters ZF swimming behavior due to DA dysfunction: In light of the decrease in DA neuron number, we asked if there was a behavioral phenotype of ziram toxicity that could be attributed to DA neuronal loss. ZF embryos were treated with 50nM ziram at 24 hpf and swimming was measured at 7 dpf in alternating light and dark cycles (Figure 2a). Vehicle-treated ZF were much more active in the dark in a stereotypical manner as previously described (Burgess and Granato 2007; Farrell et al. 2011). Ziram-treated fish swam significantly less in the dark compared to controls but no change was seen in the light (Figure 2b,c). To determine if these behavioral changes were due to DA neuronal dysfunction, we treated controls with the dopamine antagonist haloperidol and found a similar pattern as with ziram, (i.e. less swimming distance in the dark and no difference in the light). The decrease in swimming in ziram-treated fish appeared to be secondary to a presynaptic dopamine loss since apomorphine, a potent agonist of the dopamine receptors, stimulated swimming equally in ziram-treated and vehicle-treated ZF (Figure 2b,c).

ZF γ 1 synuclein forms aggregates in vitro and in vivo: α -syn aggregation appears to be central to the pathophysiology of PD. Ziram increases α -syn levels in DA neurons in primary mesencephalic cultures likely through inhibition of the proteasome (Chou et al. 2008; Wang et al. 2006). Three isoforms of synuclein (β , γ 1, and γ 2) have previously been partially characterized in ZF but none appear to be the exact orthologue to human α -syn (Milanese et al. 2012; Sun and Gitler 2008). ZF γ 1 has been previously demonstrated to be expressed widely throughout the developing ZF brain (Chen et al. 2009). Since ZF γ 1 synuclein contains N-terminal repeats and hydrophobic regions similar to that of α -syn, and expression of human α -syn rescues behavioral defects of γ 1-deficient ZF embryos (Milanese et al. 2012), we investigated the propensity of ZF γ 1's to aggregate and induce toxicity *in vitro* and *in vivo*.

Recombinant human α -syn and ZF γ 1 were incubated and monitored for β -sheet formation using ThT fluorescence. The morphology of each sample was examined at the end of the aggregation reactions by TEM (Sinha et al. 2012). The ThT fluorescence in the α -syn samples began to increase following a lag phase of ~ 10 h and reached a plateau at ~ 55 h (Figure 3A). In the ZF γ 1 samples, the lag phase was shorter, ~ 7 h, and the kinetics of ThT fluorescence increase was faster, reaching a plateau by ~ 25 h (Figure 3A). Both proteins formed abundant fibrils as determined by TEM though the fibrils differed in length. α -Syn formed long fibrils, ≥ 1 μ m in length with a diameter of 10 ± 1 nm (Figure 3B), whereas ZF γ 1 formed 20-740nm long fibrils with a diameter of 9 ± 2 nm (Figure 3C). This difference in length and abundance of the fibrils can be attributed to ZF γ 1's shorter nucleation rate, as reflected by the shorter ThT fluorescence lag phase relative to α -syn. Thus, similarly to α -syn and other amyloidogenic proteins, ZF γ 1 is an amyloidogenic protein that has the ability to form β -sheet-rich fibrils.

We previously demonstrated that overexpression of α -syn in ZF neurons led to malformed embryos, intracellular aggregates, and neuronal death (Prabhudesai et al. 2012). Here, we overexpressed ZF γ 1 in ZF neurons in order to determine if increased levels of endogenous protein induced aggregate formation, and were neurotoxic *in vivo*. In this model, ZF γ 1 was expressed under control of the *HuC* neuronal promoter as a fusion protein with T2A-DsRed. The T2A peptide is post-translationally cleaved releasing native ZF γ 1 and the fluorescent DsRed reporter in equal molar concentrations (Prabhudesai et al. 2012). Embryos overexpressing ZF γ 1 were malformed and had reduced survival compared to embryos overexpressing DsRed (Figure 4a and b). Using an antibody specific for ZF γ 1, we found that embryos overexpressing ZF γ 1 formed intracytoplasmic aggregates (Figure 4c,d). Additionally, ThS staining was observed only in neurons overexpressing ZF γ 1, whereas no staining was seen

in DsRed-expressing controls (Figure 4e and f) indicating that these aggregates contained β -sheet-rich aggregates.

Since ziram increases α -syn in primary neuronal cultures and ZF γ 1 displays many of the same characteristics as α -syn, we determined the effects of ziram on ZF γ 1 levels at 5 dpf. Western blot analysis of ZF embryo extracts probed with anti-ZF γ 1 antibody revealed a band at 17 kDa (presumed monomer, Figure 5a and Fig. S1a). A significant decrease in intensity of the 17 kDa band was observed for embryos treated with 50nM ziram compared to vehicle-treated ZF (Figure 5b). Western blots conducted under native conditions revealed a major band of 480 kDa and a minor band at 242 kDa (see Fig. S1b) for both ziram-treated and control samples suggesting that ziram does not alter the degree of oligomerization of ZF γ 1.

Ziram's toxicity is ZF γ 1 dependent: In order to understand the role of ZF γ 1 in ziram's neuronal toxicity, we knocked down ZF γ 1 expression using MO prior to ziram treatment. MO knockdown of ZF γ 1 protected telencephalic and diencephalic aminergic neurons from ziram's toxicity (Figure 6a,b).

To further explore the role of ZF γ 1 in ziram's neuronal toxicity, we utilized the molecular tweezer, CLR01. CLR01 has previously been found to reduce human α -syn toxicity by disrupting α -syn aggregation *in vivo* and *in vitro* (Acharya et al. 2014; Prabhudesai et al. 2012; Sinha et al. 2012). We have previously reported that CLR01 reduced α -syn toxicity in cell-based models and in ZF (Prabhudesai et al. 2012). Here, we found that CLR01 also inhibited recombinant ZF γ 1 fibrillation as determined by ThT fluorescence and EM (Figure 7 a-c) and reduced ziram's neurotoxicity *in vivo* as measured by the integrity of VMAT2:GFP neurons (Figure 7d). Thus, ziram's neurotoxicity appears to be dependent not only on the total ZF γ 1

levels, as suggested by the MO experiment (Figure 6), but also on formation of toxic forms of ZF γ 1, which are disrupted by CLR01 (Figure 7).

Discussion

The link between pesticide exposure and PD has become more recognized in recent years. The identification of specific toxins that increase PD risk such as paraquat, rotenone, ziram and maneb (Gatto et al. 2009; Tanner et al. 2009; Tanner et al. 2011; Wang et al. 2011), have facilitated mechanistic studies. Ziram has been shown to inhibit both the UPS and aldehyde dehydrogenase (ALDH) (Chou et al. 2008; Fitzmaurice et al. 2013; Fitzmaurice et al. 2014) but a direct link between these activities and neuronal toxicity *in vivo* is still lacking. In this study, we used a ZF model to study environmental toxins relevant to PD and found that ziram caused selective DA neuron damage with behavioral consequences. Since human α -syn is central to the pathogenesis of PD, we hypothesized that ZF γ 1 mediates ziram's neurotoxicity. In support of this hypothesis, we found that ZF γ 1 forms fibrils and is neurotoxic in a similar manner to human α -syn and that ziram's toxicity was ZF γ 1-dependent.

Although ZF offer several advantages over other animal models when studying environmental toxins, there are a number of limitations that need to be considered. In all of our studies, we used developing embryos whereas PD is a disease of aging. Embryos were exposed at 24 hpf and formation of the blood-brain barrier begins at approximately 3 dpf (Fleming et al. 2013). Additionally, the metabolism of ziram might be different in ZF embryos compared to mammals since absorption at this early age may occur orally, dermally, or through the yolk. Despite these limitations, we believe our model is valid because the results are consistent with

previous studies performed in rodents where ziram and maneb have been shown to cause selective DA-cell loss (Chou et al. 2008; Thiruchelvam et al. 2000).

The behavioral effect of ziram on ZF embryos appears to be caused by a specific deficiency in DA signaling and not simply by non-specific toxicity. Ziram decreased locomotion in the dark but not in the light in a similar manner as the dopamine antagonist haloperidol. This decrease in activity was reversed by the dopamine agonist apomorphine suggesting that the behavioral phenotype was due to a presynaptic dopamine deficiency. These results are consistent with the apparent loss of VMAT2:GFP neurons. Less specific neurotoxins decrease locomotion in both the light and the dark and would not be expected to be completely reversed by a dopamine agonist. The selective loss of DA neurons by ziram is therefore supported by both the behavioral data and the preservation of non-DA neurons (Rohon-Beard and serotonergic neurons of the Raphe Nuclei). It is possible that the loss of GFP signal does not reflect neuron loss but simply injury, yet the behavioral changes and the decrease in TH-1 support that ziram caused DA neuron injury and dysfunction.

It is not completely clear how ziram causes selective DA neuron damage but the mechanism appears to require ZF γ 1. Others have previously demonstrated that ZF γ 1 might have a similar physiologic function as human α -syn (Milanese et al. 2012) in ZF, but we were surprised to find that ZF γ 1 is neurotoxic like α -syn. Here we demonstrate that recombinant ZF γ 1 formed amyloid fibrils with similar kinetics to α -syn, and overexpression of ZF γ 1 in neurons led to formation of aggregates and neurotoxicity in almost an identical manner to human α -syn (Prabhudesai et al. 2012).

Previously, ziram was shown to inhibit the proteasome and increase accumulation of α -syn in primary neuronal cultures (Chou et al. 2008; Wang et al. 2006). Interestingly, we observed a decrease in protein levels of ZF γ 1 in ziram-treated embryos. The differences in these results likely are due to the different models used, exposure times, and methods used to measure synuclein levels. In the neuronal culture study, ziram exposures were much shorter (48h) and synuclein levels were determined only in the soma of tyrosine hydroxylase-positive neurons. Since ziram decreases protein degradation by inhibiting the proteasome, we hypothesized that synuclein accumulated in the surviving neurons. In our current study, we measured total embryonic synuclein by Western blot analysis. Since synuclein is primarily a synaptic protein in differentiated neurons *in vivo*, we hypothesize that the lower levels we measured after 120h of treatment were due to neuronal terminal loss. DA terminal loss in these studies was confirmed by the reduction of GFP fluorescence in VMAT-2 neurons, reduction of TH immunoreactivity, and behavioral abnormalities that were reversed by a dopamine agonist. The fact that reducing ZF γ 1 levels with MO almost completely protected against ziram toxicity suggests that ziram increased the formation of toxic ZF γ 1 species early in embryonic development. Overexpression of ZF γ 1 in neurons did lead to the formation of β -sheet-rich aggregates but we did not detect fibril formation with ThS *in vivo* after ziram exposure. The formation of synuclein β -sheets is dependent on several factors including concentration and time. In ziram treated embryos, ZF γ 1 might not have reached high enough concentrations or had enough time to form aggregates. Regardless, others have suggested that prefibrillar oligomers of α -synuclein may be the cause of DA neuronal toxicity (Danzer et al. 2007; Winner et al. 2011). These data suggest that the toxic effect of ziram might be mediated by toxic, soluble ZF γ 1 oligomers. This is supported by the finding that CLR01 also protected against ziram toxicity. CLR01 has previously been

demonstrated to act on amyloidogenic proteins and protect against their toxicity both *in vivo* and *in vitro* (Attar et al. 2012; Prabhudesai et al. 2012; Sinha et al. 2011). CLR01's only known activity is to remodel the self-assembly of amyloidogenic proteins into non-toxic and non-amyloidogenic structures and facilitate their clearance (Acharya et al. 2014; Attar and Bitan 2014; Prabhudesai et al. 2012).

Most neurodegenerative disorders like PD have a relatively selective pattern of neuronal loss although the mechanisms responsible for this selectivity have remained elusive. Ziram and other DTCs have been shown to inhibit the UPS, but this would not explain the selectivity of neuronal damage. It is possible that ziram's ability to inhibit ALDH in addition to its UPS-inhibiting activity, leads to selective DA damage. ALDH inhibition causes the accumulation of DOPAL in DA neurons, which is toxic (Burke et al. 2008; Casida et al. 2014; Fitzmaurice et al. 2013; Fitzmaurice et al. 2014; Panneton et al. 2010). The ZF model described here offers a powerful tool for further mechanistic studies.

Conclusions

In summary, we report that ziram, a pesticide that increases the risk of PD, causes selective DA neuron damage that is synuclein-dependent in ZF. These findings provide potentially important mechanistic implications on how ziram and possibly other environmental toxins can contribute to the pathogenesis of neurodegenerative disorders such as PD. A better understanding of these processes has the potential to illuminate pathways critical in disease formation and also highlight critical targets for future therapeutic exploitation.

References

Acharya S, Safaie BM, Wongkongkathep P, Ivanova MI, Attar A, Klarner FG, et al. 2014.

Molecular basis for preventing alpha-synuclein aggregation by a molecular tweezer. *The Journal of biological chemistry* 289:10727-10737.

Agency USEP. 2015. Label amendment- remove use on blackberry on the label per epa request, product name: Ziram 76df fungicide. 70506-173.

http://www3.epa.gov/pesticides/chem_search/ppls/070506-00173-20151002.pdf:Environmental Protection Agency.

Attar A, Ripoli C, Riccardi E, Maiti P, Li Puma DD, Liu T, et al. 2012. Protection of primary neurons and mouse brain from alzheimer's pathology by molecular tweezers. *Brain : a journal of neurology* 135:3735-3748.

Attar A, Bitan G. 2014. Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models. *Current pharmaceutical design* 20:2469-2483.

Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. 1998. Aggregation of alpha-synuclein in lewy bodies of sporadic parkinson's disease and dementia with lewy bodies. *The American journal of pathology* 152:879-884.

Barnhill LM, Bronstein JM. 2014. Pesticides and parkinson's disease: Is it in your genes? *Neurodegenerative disease management* 4:197-200.

Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. 2000.

Chronic systemic pesticide exposure reproduces features of parkinson's disease. *Nature neuroscience* 3:1301-1306.

Biancalana M, Koide S. 2010. Molecular mechanism of thioflavin-t binding to amyloid fibrils.

Biochimica et biophysica acta 1804:1405-1412.

Bretau S, Li Q, Lockwood BL, Kobayashi K, Lin E, Guo S. 2007. A choice behavior for morphine reveals experience-dependent drug preference and underlying neural substrates in developing larval zebrafish. *Neuroscience* 146:1109-1116.

Briquet M, Sabadie-Pialoux N, Goffeau A. 1976. Ziram, a sulfhydryl reagent and specific inhibitor of yeast mitochondrial dehydrogenases. *Archives of biochemistry and biophysics* 174:684-694.

Brown TP, Rumsby PC, Capleton AC, Rushton L, Levy LS. 2006. Pesticides and parkinson's disease--is there a link? *Environmental health perspectives* 114:156-164.

Burgess HA, Granato M. 2007. Modulation of locomotor activity in larval zebrafish during light adaptation. *The Journal of experimental biology* 210:2526-2539.

Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, et al. 2008. Aggregation of alpha-synuclein by dopal, the monoamine oxidase metabolite of dopamine. *Acta neuropathologica* 115:193-203.

Casida JE, Ford B, Jinsmaa Y, Sullivan P, Cooney A, Goldstein DS. 2014. Benomyl, aldehyde dehydrogenase, dopal, and the catecholaldehyde hypothesis for the pathogenesis of parkinson's disease. *Chemical research in toxicology*.

Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. 2004.

Alpha-synuclein locus duplication as a cause of familial parkinson's disease. *Lancet* 364:1167-1169.

Chen YC, Cheng CH, Chen GD, Hung CC, Yang CH, Hwang SP, et al. 2009. Recapitulation of zebrafish *snca* expression pattern and labeling the habenular complex in transgenic zebrafish using green fluorescent protein reporter gene. *Developmental dynamics : an official publication of the American Association of Anatomists* 238:746-754.

Chou AP, Maidment N, Klintenberg R, Casida JE, Li S, Fitzmaurice AG, et al. 2008. Ziram causes dopaminergic cell damage by inhibiting e1 ligase of the proteasome. *The Journal of biological chemistry* 283:34696-34703.

Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. 2007. Different species of alpha-synuclein oligomers induce calcium influx and seeding. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 27:9220-9232.

Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. 2007. Projected number of people with parkinson disease in the most populous nations, 2005 through 2030. *Neurology* 68:384-386.

Farrell TC, Cario CL, Milanese C, Vogt A, Jeong JH, Burton EA. 2011. Evaluation of spontaneous propulsive movement as a screening tool to detect rescue of parkinsonism phenotypes in zebrafish models. *Neurobiology of disease* 44:9-18.

Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, et al. 2004. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. *Annals of neurology* 55:174-179.

Feany MB, Bender WW. 2000. A drosophila model of parkinson's disease. *Nature* 404:394-398.

Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA, O'Donnell KC, et al. 2013.

Aldehyde dehydrogenase inhibition as a pathogenic mechanism in parkinson disease.

Proceedings of the National Academy of Sciences of the United States of America 110:636-641.

Fitzmaurice AG, Rhodes SL, Cockburn M, Ritz B, Bronstein JM. 2014. Aldehyde dehydrogenase variation enhances effect of pesticides associated with parkinson disease.

Neurology 82:419-426.

Fleming A, Diekmann H, Goldsmith P. 2013. Functional characterisation of the maturation of the blood-brain barrier in larval zebrafish. *PloS one* 8:e77548.

Fokkens M, Schrader T, Klarner FG. 2005. A molecular tweezer for lysine and arginine. *Journal of the American Chemical Society* 127:14415-14421.

Gatto NM, Cockburn M, Bronstein J, Manthripragada AD, Ritz B. 2009. Well-water consumption and parkinson's disease in rural california. *Environmental health perspectives* 117:1912-1918.

Gatto NM, Rhodes SL, Manthripragada AD, Bronstein J, Cockburn M, Farrer M, et al. 2010. Alpha-synuclein gene may interact with environmental factors in increasing risk of parkinson's disease. *Neuroepidemiology* 35:191-195.

Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, et al. 2012. Head injury, alpha-synuclein repl, and parkinson's disease. *Annals of neurology* 71:40-48.

Goldman SM. 2014. Environmental toxins and parkinson's disease. *Annual review of pharmacology and toxicology* 54:141-164.

Gunnarsson L, Jauhiainen A, Kristiansson E, Nerman O, Larsson DG. 2008. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. *Environmental science & technology* 42:5807-5813.

Haendel MA, Tilton F, Bailey GS, Tanguay RL. 2004. Developmental toxicity of the dithiocarbamate pesticide sodium metam in zebrafish. *Toxicological sciences : an official journal of the Society of Toxicology* 81:390-400.

Hope AD, Myhre R, Kachergus J, Lincoln S, Bisceglia G, Hulihan M, et al. 2004. Alpha-synuclein missense and multiplication mutations in autosomal dominant parkinson's disease. *Neuroscience letters* 367:97-100.

Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. 2004. Causal relation between alpha-synuclein gene duplication and familial parkinson's disease. *Lancet* 364:1169-1171.

International Parkinson Disease Genomics C, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, et al. 2011. Imputation of sequence variants for identification of genetic risks for parkinson's disease: A meta-analysis of genome-wide association studies. *Lancet* 377:641-649.

Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. 1998. Ala30pro mutation in the gene encoding alpha-synuclein in parkinson's disease. *Nature genetics* 18:106-108.

Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, et al. 2006.

Collaborative analysis of alpha-synuclein gene promoter variability and parkinson disease.

JAMA : the journal of the American Medical Association 296:661-670.

McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta

DA, et al. 2002. Environmental risk factors and parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. *Neurobiology of disease* 10:119-127.

Milanese C, Sager JJ, Bai Q, Farrell TC, Cannon JR, Greenamyre JT, et al. 2012. Hypokinesia and reduced dopamine levels in zebrafish lacking beta- and gamma1-synucleins. *The Journal of biological chemistry* 287:2971-2983.

Nishioka K, Hayashi S, Farrer MJ, Singleton AB, Yoshino H, Imai H, et al. 2006. Clinical heterogeneity of alpha-synuclein gene duplication in parkinson's disease. *Annals of neurology* 59:298-309.

Panneton WM, Kumar VB, Gan Q, Burke WJ, Galvin JE. 2010. The neurotoxicity of dopal: Behavioral and stereological evidence for its role in parkinson disease pathogenesis. *PloS one* 5:e15251.

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. 1997. Mutation in the alpha-synuclein gene identified in families with parkinson's disease. *Science* 276:2045-2047.

Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, et al. 2012. A novel "molecular tweezer" inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
9:464-476.

R. Jeroen Pasterkamp MPS, J. Peter H. Burbach. 2009. Development and engineering of dopamine neurons. Austin, Texas:Landes Bioscience.

Rink E, Wullimann MF. 2002. Development of the catecholaminergic system in the early zebrafish brain: An immunohistochemical study. *Brain research Developmental brain research* 137:89-100.

Ritz B, Rhodes SL, Bordelon Y, Bronstein J. 2012. Alpha-synuclein genetic variants predict faster motor symptom progression in idiopathic parkinson disease. *PloS one* 7:e36199.

Ryan SD, Dolatabadi N, Chan SF, Zhang X, Akhtar MW, Parker J, et al. 2013. Isogenic human ipsc parkinson's model shows nitrosative stress-induced dysfunction in mef2-pgc1alpha transcription. *Cell* 155:1351-1364.

Sagasti A, Guido MR, Raible DW, Schier AF. 2005. Repulsive interactions shape the morphologies and functional arrangement of zebrafish peripheral sensory arbors. *Current biology* : CB 15:804-814.

Schweitzer J, Lohr H, Filippi A, Driever W. 2012. Dopaminergic and noradrenergic circuit development in zebrafish. *Developmental neurobiology* 72:256-268.

Sheng D, Qu D, Kwok KH, Ng SS, Lim AY, Aw SS, et al. 2010. Deletion of the wd40 domain of Irrk2 in zebrafish causes parkinsonism-like loss of neurons and locomotive defect. *PLoS genetics* 6:e1000914.

Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. 2003. Alpha-synuclein locus triplication causes parkinson's disease. *Science* 302:841.

Sinha S, Lopes DH, Du Z, Pang ES, Shanmugam A, Lomakin A, et al. 2011. Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. *Journal of the American Chemical Society* 133:16958-16969.

Sinha S, Du Z, Maiti P, Klarner FG, Schrader T, Wang C, et al. 2012. Comparison of three amyloid assembly inhibitors: The sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer clr01. *ACS chemical neuroscience* 3:451-458.

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in lewy bodies. *Nature* 388:839-840.

Sun Z, Gitler AD. 2008. Discovery and characterization of three novel synuclein genes in zebrafish. *Developmental dynamics : an official publication of the American Association of Anatomists* 237:2490-2495.

Talbiersky P, Bastkowski F, Klarner FG, Schrader T. 2008. Molecular clip and tweezer introduce new mechanisms of enzyme inhibition. *Journal of the American Chemical Society* 130:9824-9828.

Tang W, Ehrlich I, Wolff SB, Michalski AM, Wolf S, Hasan MT, et al. 2009. Faithful expression of multiple proteins via 2a-peptide self-processing: A versatile and reliable method for manipulating brain circuits. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 29:8621-8629.

Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, et al. 2009. Occupation and risk of parkinsonism: A multicenter case-control study. *Archives of neurology* 66:1106-1113.

Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. 2011. Rotenone, paraquat, and parkinson's disease. *Environmental health perspectives* 119:866-872.

Teraoka H, Urakawa S, Nanba S, Nagai Y, Dong W, Imagawa T, et al. 2006. Muscular contractions in the zebrafish embryo are necessary to reveal thiuram-induced notochord distortions. *Toxicology and applied pharmacology* 212:24-34.

Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. 2000. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: Implications for parkinson's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 20:9207-9214.

Trinh J, Farrer M. 2013. Advances in the genetics of parkinson disease. *Nature reviews Neurology* 9:445-454.

Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B. 2011. Parkinson's disease risk from ambient exposure to pesticides. *European journal of epidemiology* 26:547-555.

Wang XF, Li S, Chou AP, Bronstein JM. 2006. Inhibitory effects of pesticides on proteasome activity: Implication in parkinson's disease. *Neurobiology of disease* 23:198-205.

Wen L, Wei W, Gu W, Huang P, Ren X, Zhang Z, et al. 2008. Visualization of monoaminergic neurons and neurotoxicity of mptp in live transgenic zebrafish. *Developmental biology* 314:84-92.

Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. 2011. In vivo demonstration that alpha-synuclein oligomers are toxic. *Proceedings of the National Academy of Sciences of the United States of America* 108:4194-4199.

Xi Y, Noble S, Ekker M. 2011. Modeling neurodegeneration in zebrafish. *Current neurology and neuroscience reports* 11:274-282.

Figure Legends

Figure 1. Ziram is selectively toxic to dopaminergic neurons. VMAT2 ZF embryos were exposed to vehicle (a) and 50nM ziram (b) at 24 hpf. Neuronal counts for the telencephalic (TC) and diencephalic (DC) clusters were conducted at 5 dpf (n=5). A 30% decrease in telencephalic (c) and 39% decrease in diencephalic neurons (d), were observed in ziram-treated fish. Ziram's toxicity did not extend to Rohon-Beard neurons (5 dpf, n=7) after 50nM ziram exposure (f) compared to vehicle controls (e). Raphe Nuclei neurons are also labeled in VMAT2:GFP fish (serotonergic neurons) and were unaffected by ziram exposure (i) compared to vehicle controls (h). Raphe Nuclei neuron counts are shown in j. Scale bar = 500 μ m. Two-tailed student t-test. *p<.05, **p<.01.

Figure 2. Ziram causes alterations in ZF motor behavior. Movement was tracked for larval ZF at 7 dpf (n=24). Distance's greater than 2 mm were tracked under an alternating light (yellow)/dark cycle (grey) (a). A 24.7% decrease (p<.05) in distance traveled during periods of dark was observed in ziram-treated ZF relative to vehicle-treated ZF(b) but no significant difference was observed in the light (c). A similar pattern of swimming, less in the dark but no difference in the light, was measured when ZF were treated with the dopamine antagonist haloperidol (b and c). The dopamine agonist apomorphine increased swimming to a similar degree in the ziram-treated and control ZF suggesting that the post-synaptic dopaminergic system remains intact. No significant difference in motor behavior was observed for ziram + apomorphine vs. apomorphine alone for light or dark conditions. All treatment groups were

compared to vehicle control for statistical analysis. * $p < .05$, *** $p < .001$, **** $p < .0001$, one way ANOVA.

Figure 3. ZF $\gamma 1$ synuclein aggregates and forms fibrils similarly to human α -synuclein.

Recombinant human α -syn (hSyn) or ZF $\gamma 1$ (both 150 μ M) were incubated over a 66-hour period and thioflavin T fluorescence was monitored (a). The morphology of hSyn (B) and ZF $\gamma 1$ (c) was examined at the end of the aggregation reaction using TEM (scale bar = 0.2 μ m).

Figure 4. Overexpression of ZF $\gamma 1$ *in vivo* causes intracellular aggregation of synuclein.

Embryos were injected with constructs for Huc-T2A-DsRed (a) or Huc- $\gamma 1$ -T2A-DsRed (b), embryos shown at 2 dpf (scale bar = 100 μ m). Sectioned embryos were stained with a primary antibody for ZF $\gamma 1$. HuC-DsRed (c) injected embryos did not have intracellular ZF $\gamma 1$ aggregates, while embryos injected with HuC-ZF $\gamma 1$ (d) were found to have intracellular ZF $\gamma 1$ aggregates (blue arrow) (scale bar = 10 μ m). To determine if ZF $\gamma 1$ formed β -pleated sheets *in vivo*, embryos injected with HuC-DsRed and Huc- $\gamma 1$ -T2A-DsRed were stained with ThS (scale bar = 10 μ m). Only neurons overexpressing ZF $\gamma 1$ (f) were ThS positive (e).

Figure 5. Ziram decreases ZF $\gamma 1$ levels. Embryos were treated with ziram or vehicle and ZF $\gamma 1$ levels were determined by Western blot analysis at 5dpf (normalized to tubulin). A 69.3% decrease in band density for ZF $\gamma 1$ was observed for samples treated with 50nM ziram (a,b, n=4). * $p < .05$ two-tailed student t-test.

Figure 6: Ziram's toxicity is ZF γ 1-dependent. ZF γ 1 expression was reduced using a specific morpholino (MO) and a scrambled MO was used as a control. Ziram treatment began at 24 hpf. Neuronal counts (normalized to vehicle + scramble/ γ 1 MO) for γ 1 MO injected embryos (n=14). An 86.8% increase in labeled telencephalic (a) and 45.1% increase in labeled diencephalic (b) VMAT2 neurons at 3dpf was observed for fish treated with ziram + γ 1 MO vs. ziram + scramble MO. *p<.05, **p<.01, student t-test

Figure 7. CLR01 inhibits ZF γ 1 aggregation in vitro and protects against ziram's toxicity in vivo. Time-dependent change in normalized ThT fluorescence over 14 days for 100 μ M γ 1 incubated in the absence or presence of CLR01 (a). The first and last 130 hours are shown (N=4). Electron micrographs of ZF γ 1 alone (b), and ZF γ 1 with CLR01 (c) in equimolar ratio (scale bar = 100 nm) obtained on day 9 or 10 of each reaction (ANOVA, p < 0.0001). CLR01 treatment protected against ziram toxicity (50nM; n=6) to VMAT2 neurons in the diencephalic cluster (e) but did not reach statistical significance in the telencephalic cluster (d) at 5 dpf. **p<.01, student t-test.

Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.




Figure 6.




Figure 7.

